These collective findings underscore the potential significance of menin inhibitors as crucial therapeutic targets for patients with KMT2A-mutated acute leukemia, with ongoing evaluation of combinatorial strategies offering promising avenues for further exploration and potential clinical benefit. Here, KMT2A is linked to acute leukemia.